Showing 1661-1670 of 7242 results for "".
Treatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.Advances in PsO: Targeting IL-23
https://practicaldermatology.com/conferences/aad-summer-2021/advances-in-pso-targeting-il-23/19974/George Han, MD, PhD reviews the latest data available on IL-23 inhibitors for the treatment of psoriasis. He discusses the specific benefits of guselkumab, tildrakizumab, and risankizumab and shares insights about how they fit into the overall psoriasis treatment arsenal.Inclusivity: A Concerted Effort
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/inclusivity-a-concerted-effort/19915/Historical events and recent developments contribute to some patients’ skepticism of medicine in general and dermatology specifically. Hear what panelists say about the best approaches to expand inclusivity in research, clinical trials, and patient care. It will take a concerted effort to overcome cQuarantine Quorum: Circling the Wagons
https://practicaldermatology.com/topics/practice-management/quarantine-quorum-circling-the-wagons/18180/With Quarantine Quorum, host Neal Bahtia, MD provides a diary of life during the COVID-19 pandemic, talking to members of the dermatology community as they adapt to ongoing changes in their personal and private lives. In this edition, Hilary Baldwin, MD; Adam J. Friedman, MD; Mark Kaufmann, MD; andCOVID-19 Impact: iPledge and Isotretinoin Prescribing
https://practicaldermatology.com/topics/acne-rosacea/covid-19-impact-ipledge-and-isotretinoin-prescribing/19763/For patients on isotretinoin, complying with the iPledge program while treating patients virtually can be challenging. Joshua Zeichner, MD discusses new FDA guidance that allows female patients to take OTC pregnancy tests in order to continue treatment. He also discusses when patients do and do notAdvances in Tattoo Removal and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-tattoo-removal-and-more/19756/Eric Bernstein, MD shares insights on the benefits of picosecond domain lasers for everything from rejuvenation to tattoo removal. He discusses his recent experience with the 730nm handpiece and its efficacy on multiple ink colors and all skin types. In addition, he talks about other new technologieTaking “picture perfect” before and after photos
https://practicaldermatology.com/topics/practice-management/taking-picture-perfect-before-and-after-photos/19751/You probably know the importance of including before and after photos on your dermatology website. However, you might be wondering how to create a professional looking image gallery without a photographer on call. Check out the latest video from Ekwa Marketing to find out!Light & Bright: A new treatment to illuminate your practice
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/light-bright-a-new-treatment-to-illuminate-your-practice/19746/Join Matthew Mahlberg, MD as he introduces the new Light & Bright treatment. Using the patented Ellipse IPL and Frax 1550 technologies on the Nordlys system, the Light & Bright treatment reduces pigmentation & redness and improves textural irregularities. Hear the results of a clinical sGalderma's Future, Allergan's Bonti Buy, and Sebacia Clearance
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-s-future-allergan-s-bonti-buy-and-sebacia-clearance--xgheloga/18233/Nestle's Board says it has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group's strategic scope and expects a review of strategic options for Nestlé Skin Health to be complete by mid-2019. Allergan is acquiring Bonti for 195 million dABD Eyes Mohs Certification, Sun's Ilumya Approved, FUE Update
https://practicaldermatology.com/topics/psoriasis/dermwiretv-abd-eyes-mohs-certification-sun-s-ilumya-approved-fue-update/18319/The American Board of Dermatology has notified the American Board of Medical Specialties it wants to offer a subspecialty certificate in Micrographic Dermatologic Surgery. Dermatologists react. Ilumya or tildrakizumab from Sun Pharma is approved for moderate to severe psoriasis. Medicine the Musical